Skip to main content

Table 1 Characteristics of the population at baseline

From: Role of systemic inflammation scores for prediction of clinical outcomes in patients treated with atazanavir not boosted by ritonavir in the Italian MASTER cohort

Variable

N

%

Qualitative

  

Gender

 Female

168

38.5%

 Male

268

61.5%

Risk factors for HIV acquisition

 Heterosexual transmission

203

46.6%

 MSM

103

23.6%

 IDU

111

25.5%

 Other/unknown

19

4.4%

Nationality

 Italian

372

85.3%

 Non Italian

64

14.7%

AIDS events

 0

332

76.1%

 1

58

13.3%

 2

23

5.3%

 3+

23

5.3%

CD4+ T cell count (cells/mm3)

  ≤ 200

70

16.1%

  > 200

366

83.9%

HIV RNA (copies/mL)

  ≤ 50

269

61.7%

 51-5000

72

16.5%

  > 5000

95

21.8%

Fib-4 score

  ≥ 1.45

353

81%

 1.46-3.25

66

15.1%

  > 3.25

17

3.9%

HBsAg

 Negative

354

81.2%

 Positive

8

1.8%

 Unknown

74

17%

HCV Ab

 Negative

256

58.7%

 Positive

71

16.3%

 Unknown

109

25%

cART exposure

 NRTI

432

99.1%

 TDF

254

58.3

 ABC

306

70.2%

 NNRTI

251

57.6%

 PI

436

100%

 Other

57

13.1%

Quantitative

Median

IQR

Age

42.72

(37.68-47.02)

BMI (Kg/m2)

23.64

(20.96-25.93)

CD4+ T cell count cells/mm3

486.4

(275.2-660)

Total cholesterol (mg/dl)

191.4

(153-225)

 HDL

44.81

(35-51)

 LDL

116.5

(90.75-136)

Triglycerides (mg/dl)

183.3

(89-221)

Serum glucose (mg/dl)

88.89

(82-97)

Bilirubin (mg/dl)

0.817

(0.4-1.01)

γGT (IU/L)

63.38

(20-62)

eGFR (mL/min/1.73 m2)

101.9

(90.28-114.2)

Number of switches in the NRTI backbone

4

(2-8)

  1. Abbreviations: N number, HIV human immuno-deficiency virus, AIDS acquired immune deficiency syndrome, MSM men have sex with men, IDU intravenous drug use, HCV Ab hepatitis C virus antibodies, HBsAg Hepatitis B virus surface antigen, Fib-4 fibrosis four score, PI proteases inhibitor, cART combination antiretroviral therapy, γGT γ-glutammil-transpeptidase, BMI body mass index, eGFR estimated glomerular filtration rate, NNRTI Non-Nucleoside Reverse Transcriptase Inhibitors, NRTI Nucleoside Reverse Transcriptase Inhibitors, ABC: abacavir, IQR interquartile range